Infliximab in refractory coeliac disease

Eur J Gastroenterol Hepatol. 2005 Jun;17(6):603-4. doi: 10.1097/00042737-200506000-00002.

Abstract

Coeliac disease is generally well controlled with gluten-free diet but a small proportion of patients require corticosteroids or immunomodulatory agents. Response to anti-tumour necrosis factor (anti-TNF) agents raises interesting questions about both the pathogenesis of coeliac disease and the mechanism of action of anti-TNF agents. Refractory coeliac disease poses a therapeutic challenge to clinicians and carefully selected patients may benefit from anti-TNF therapy.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Celiac Disease / drug therapy*
  • Celiac Disease / immunology
  • Gastrointestinal Agents / therapeutic use*
  • Humans
  • Infliximab
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal
  • Gastrointestinal Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab